Stoke Therapeutics, Inc. (STOK)

Market Cap	1.29B
Revenue (ttm)	199.89M
Net Income (ttm)	52.49M
Shares Out	54.80M
EPS (ttm)	0.91
PE Ratio	25.83
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,030,995
Open	24.00
Previous Close	23.88
Day's Range	22.45 - 24.60
52-Week Range	5.35 - 24.60
Beta	1.14
Analysts	Strong Buy
Price Target	26.60 (+13.38%)
Earnings Date	Nov 4, 2025

About STOK

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2019
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: STOK
• Website: https://www.stoketherapeutics.com

Financial Performance

In 2024, Stoke Therapeutics's revenue was $36.56 million, an increase of 316.34% compared to the previous year's $8.78 million. Losses were -$88.98 million, -15.01% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $26.6, which is an increase of 13.38% from the latest price.

Price Target

$26.6

(13.38% upside)

Analyst Consensus: Strong Buy